Trial Profile
Open-label single-arm phase II study of Alimta [pemetrexed] in combination with oxaliplatin as first-line therapy in advanced gastric carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Oxaliplatin (Primary) ; Pemetrexed (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- 28 Aug 2006 Status change
- 28 Aug 2006 Status change
- 28 Aug 2006 Status change